scispace - formally typeset
B

Barry R. Davis

Researcher at University of Texas at Austin

Publications -  351
Citations -  50989

Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.

Papers
More filters
Journal ArticleDOI

Rapid Decreases in Blood Pressure from Antihypertensive Treatment were Associated with Increased Cancer Mortality in the Systolic Hypertension in the Elderly Program

Joel N. Swerdel, +7 more
- 01 Aug 2014 - 
TL;DR: Large SBP decreases early in HTDT were associated with an increased risk of cancer-related death during a 15-year follow-up, suggesting rapid decreases in blood pressure following HTDT may be a risk factor for cancer.
Journal ArticleDOI

Evaluating the effects of treatment switching with randomization as an instrumental variable in a randomized controlled trial

Sara Jimenez, +3 more
- 28 Feb 2017 - 
TL;DR: This study utilized simulated data based on an ongoing randomized clinical trial (RCT) to evaluate the effects of treatment switching with randomization as an instrumental variable at differing levels of treatment crossovers, for continuous and binary outcomes.
Journal ArticleDOI

Results of monotherapy in allhat: on-treatment analyses

Jeffrey A. Cutler, +8 more
- 01 May 2004 - 
Journal ArticleDOI

Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes.

Joshua I. Barzilay, +8 more
- 11 Jul 2018 - 
TL;DR: A rapid decline in estimated glomerular filtration rate over 2 years in a large hypertensive cohort was associated with similar risks for overall cardiovascular disease in people with or without diabetes mellitus, but with higher all-cause mortality, heart failure, and end stage renal disease risk inPeople with diabetes.
Journal ArticleDOI

Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?

Joshua I. Barzilay, +2 more
- 01 May 2016 - 
TL;DR: Recently, several studies and meta-analyses have reported that RAS blocking agents do not offer any advantages compared to other antihypertensive medications for the treatment of adults with DM.